As the world enters one of the largest infrastructure and technology investment cycles in history, BioLargo, Inc., a developer of innovative technologies addressing environmental, energy, and medical challenges, has captured global attention with its mesmerizing array of impactful solutions for the world’s biggest problems:
- Toxic chemicals/PFAS, which results in a staggering 158M fatal and near-fatal incidents to Americans annually.
- Lithium’s ongoing fire problems and the raging AI battery grid storage global dilemma.
- The catastrophic infection and wound care problems that are linked to 1.7 million hospital-acquired infections every year in America.
“We are at the apex of a once-in-a-century energy transition,” BioLargo CEO Dennis Calvert says. “A rare convergence of macroeconomic, geopolitical, and technological forces has created an inflection point for energy infrastructure changes – and significant investment from Wall Street and around the world.”
U.S. strategic policy, Calvert says, “is actively reshoring high-tech manufacturing, securing critical mineral supply chains, and restoring domestic industrial leadership as a foundation for global competitiveness.”
Simultaneously, the AI revolution is driving what may be the largest infrastructure expansion in human history. Energy demand is expected to double within the next 15 years, Calvert says, while demand for long-duration energy storage is projected to increase six- to seven-fold—becoming a cornerstone of grid resilience, data center expansion, and AI scalability.
“We sit squarely at the apex of these trends,” he says. “Its long-duration energy storage technology called Cellinity, addresses the industry’s most critical constraints: a 20-year operating life, high energy density, strong round-trip efficiency, low-cost and domestically sourced materials, and a credible end-of-life solution.
“This technical advantage,” he continues, “is reinforced by a deeply experienced engineering and commercialization team capable of scaling manufacturing and deployment globally.”
BioLargo’s business model is a franchise-style joint venture strategy “aligns perfectly” with U.S. tax credits and localization incentives, while enabling partners worldwide to invest, build manufacturing capacity, develop skilled workforces, and share in the value creation.
“Our ‘share-the-wealth’ model accelerates adoption, de-risks expansion, and positions BioLargo as a strategic platform—one that advances national priorities, strengthens global energy security, and powers the future of AI and sustainable growth.”
BioLargo closed 2025 “focused on execution, disciplined capital deployment, and long-term value creation,” Calvert says. “Global investment trends – which are driven by artificial intelligence, data centers, electrification, energy storage, and environmental remediation – are placing increasing demands on water systems, energy infrastructure, and regulatory compliance.”
BioLargo’s portfolio of enabling technologies “addresses these challenges at the system level, where performance, sustainability, and economics increasingly converge,” Calvert says.
2025: A Year Defined by Disciplined Progress
With its humble $57M market cap, BioLargo significantly advanced multiple technology platforms through continued development, validation, and early-stage deployment activities, garnering partnerships and massive global attention to its impactful work.
"Rather than pursuing rapid expansion, we remained focused on capital efficiency, technical rigor, and building durable pathways toward commercialization across our portfolios,” Calvert says.
"This approach," he quickly adds, "reflects our long-standing strategy to develop high-impact technologies patiently, validate them thoroughly, and position us to serve large and growing markets where demand is driven by structural forces rather than short-term trends."
[video width="1920" height="1080" mp4="/media/2025/12/BIOLARGO_TradeWars.mp4"][/video]
[video width="1920" height="1080" mp4="/media/2025/12/BIOLARGO_TableSalt.mp4"][/video]
[video width="1920" height="1080" mp4="/media/2025/12/BIOLARGO_AIAchillesHeel.mp4"][/video]
From Development to Deployment: The New Jersey Initiatives
BioLargo advanced several project initiatives with the State of New Jersey in 2025 that reflect the company's progression from development toward real-world application.
These initiatives are related to PFAS treatment and advanced AI battery and grid-scale manufacturing in South Jersey, involving public–private collaboration aligned with state and regional infrastructure priorities.
Additionally, BioLargo's subsidiary, Clyra Medical Technologies, Inc. made sizable capital investments to expand operational capacity for Clyra's highly anticipated 2026 launch of its medical device products to combat the current catastrophic infection and wound care problems that are tied to 1.7 million hospital acquired infections every year in America.
“These initiatives represent tangible progress toward deployment and reflect growing institutional engagement with BioLargo's technologies," Calvert says. “Our engineering team has a long and successful history of working with industry and governments in the State of New Jersey.”
Alignment with a Historic Investment Cycle
BioLargo’s technologies are” increasingly aligned with the needs of industries at the center of global capital investment,” Calvert says. “Data centers and advanced manufacturing facilities face intensifying constraints related to water use, emissions, energy efficiency, and environmental compliance.
“The prevailing energy storage systems continue to require improvements in safety, materials performance, and environmental impact."
BioLargo's solutions are designed as enabling technologies intended to support more efficient, sustainable, innocuous and compliant system-level performance as scale and regulatory requirements increase.
Calvert says: "The world is looking to avoid and break down current geopolitical supply chain constraints that dominate the energy and energy storage industry and most certainly our nation.”
Medical Platform Progress and Commercial Positioning
During 2025, BioLargo's medical platform, Clyra Medical Technologies, advanced through coordinated commercial, product development, and clinical engagement activities.
“What began as a research-intensive effort matured into a commercial-stage platform supported by multiple development and market-entry initiatives,” Clyra President Steve Harrison says.
“Clyra's products are commercially available, and distribution efforts are underway to support broader market entry beginning in 2026,” Harrison says. “Expanded product designs are under development to support additional clinical and commercial applications.”
“Our clinical work,” he adds, “is well underway with key opinion leaders, providing real-world application experience. These activities are expected to contribute to scientific and medical presentations at professional forums in early 2026, subject to customary clinical, regulatory, and publication considerations. This is an important milestone in the platform's evolution from development into active commercialization.”
A Portfolio Perspective on Long-Term Value
BioLargo is structured as a portfolio of independently developed technologies, each intended to address large, global markets shaped by environmental necessity, infrastructure investment, and regulatory pressure.
Management evaluates progress through a sum-of-the-parts perspective, recognizing that the intrinsic value of such a portfolio may not be reflected in the trading dynamics typical of early-stage public companies.
For 18 years, BioLargo has invested patient capital into building its portfolio with intention, pursuing a capital-conserving strategy and assembling highly qualified teams around differentiated technologies,” according to Calvert.
“We continue to refine our commercialization strategies as we prioritize opportunities with the potential to support long-term value creation,” he says. “As we enter 2026, global priorities related to infrastructure expansion, energy storage, environmental remediation, and medical innovation continue to advance and evolve.”
With multiple technology platforms maturing, early deployment initiatives progressing, and commercial medical products preparing for broader market entry.
“While the timing and scale of market adoption cannot be predicted with certainty, BioLargo remains focused on executing its strategy and advancing its technologies responsibly,” he says. “We have entered the next phase of development with the right technologies, the right teams, a disciplined strategy, and timing that is increasingly aligned with years of preparation.”
Copyright © 2025 California Business Journal. All Rights Reserved.
For California Business Journal Disclaimers, go to /terms-conditions/.
